Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

635
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
635
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.1K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.0K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.4K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.4K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

3.4K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial and Socioeconomic Differences in Real-World Use of Biologic Therapy for Asthma.

Journal of asthma and allergy·2026
Same author

Machine learning prediction of asthma and allergic rhinitis in children with early-onset atopic dermatitis.

The Journal of allergy and clinical immunology·2026
Same author

Characterization of Patients with COPD and GOLD E Classification in the United States.

International journal of chronic obstructive pulmonary disease·2026
Same author

Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study.

Respiratory research·2026
Same author

Patterns of healthcare visits and vaccination among adolescents and young adults 16-23-years-old: a retrospective US claims database analysis.

Current medical research and opinion·2025
Same author

Hemoglobin stability impact on healthcare resource utilization and costs among dialysis-dependent patients with anemia of end-stage kidney disease.

BMC nephrology·2025

Related Experiment Video

Updated: Dec 20, 2025

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K

COPD exacerbation costs in the IMPACT study: a within-trial analysis.

Michael R Bogart1, Sari D Hopson, Huai-Che Shih

  • 1US Value Evidence and Outcomes, GlaxoSmithKline plc, 5 Moore Dr, Research Triangle Park, Durham, NC.

The American Journal of Managed Care
|May 22, 2020
PubMed
Summary

Triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) significantly reduced costs associated with moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations compared to dual therapies in the US. This finding highlights the economic benefits of FF/UMEC/VI for COPD management.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

731
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.2K

Related Experiment Videos

Last Updated: Dec 20, 2025

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

731
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.2K

Area of Science:

  • Pulmonary Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Exacerbations represent a significant cost driver in chronic obstructive pulmonary disease (COPD) management.
  • Understanding the economic impact of different treatment regimens is crucial for healthcare payers.
  • Previous studies have focused on clinical outcomes, but economic evaluations comparing triple and dual therapies for COPD are essential.

Purpose of the Study:

  • To evaluate the costs associated with moderate and severe COPD exacerbations from a US payer perspective.
  • To compare the economic impact of triple therapy (fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI]) versus dual therapies (FF/VI or UMEC/VI).

Main Methods:

  • A post hoc economic analysis utilizing data from the InforMing the PAthway of COPD Treatment (IMPACT) study.
  • Inclusion of 10,355 patients treated with either FF/UMEC/VI, FF/VI, or UMEC/VI.
  • Primary endpoint: cost differences related to 1-year on-treatment combined moderate and severe COPD exacerbation events.

Main Results:

  • The mean 1-year on-treatment cost for exacerbations was lowest with FF/UMEC/VI ($4913) compared to UMEC/VI ($6205).
  • FF/UMEC/VI demonstrated statistically significant cost savings compared to FF/VI (-$549) and UMEC/VI (-$1292).
  • These cost differences were significant for both combined moderate/severe exacerbations and when analyzed separately.

Conclusions:

  • Treatment with FF/UMEC/VI resulted in lower exacerbation-related costs in the US healthcare system compared to FF/VI or UMEC/VI.
  • The findings support the economic value of triple therapy in managing COPD exacerbations.
  • FF/UMEC/VI offers a cost-effective strategy for reducing the economic burden of COPD exacerbations.